Kazia Therapeutics vs Lyell Immunopharma
Lyell Immunopharma is the larger business, with $36,000 of revenue in fiscal 2025 against $27,211 for Kazia Therapeutics (1.3 times as much). Lyell Immunopharma grew faster (-41.0% against -98.2%). Kazia Therapeutics kept more of each dollar of sales as profit: a net margin of -49290.5% against -762355.6%.
| Latest fiscal year | Kazia TherapeuticsKZIA, 2025 | Lyell ImmunopharmaLYEL, 2025 |
|---|---|---|
| Revenue | $27,211 | $36,000 |
| Revenue growth | -98.2% | -41.0% |
| Net income | −$13.4m | −$274m |
| Operating margin | — | -748344.4% |
| Net margin | -49290.5% | -762355.6% |
| Return on equity | — | -87.0% |
| Free cash flow | −$8.6m | −$151m |
| Cash | $2.9m | $60.2m |
| Total debt | $260,291 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 161 |
| Market value | $8.8m | $252m |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 29 sales |